Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Nov;9(11):4226-4229.
doi: 10.21037/jtd.2017.10.31.

The future of immune checkpoint blockade immunotherapy: towards personalized therapy or towards combination therapy

Zhiwei Hu  1
Affiliations
Editorial

The future of immune checkpoint blockade immunotherapy: towards personalized therapy or towards combination therapy

Zhiwei Hu. J Thorac Dis. 2017 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Z Hu is co-inventor of the first generation tissue factor-targeting “neovascular-targeted immunoconjugates” (ICON) and is the inventor of a second and a third generation tissue factor-targeting ICONs, named L-ICON1 and L-ICON3 (Patents Pending).

Comment on

References

    1. Brunet JF, Denizot F, Luciani MF, et al. A new member of the immunoglobulin superfamily--CTLA-4. Nature 1987;328:267-70. 10.1038/328267a0 - DOI - PubMed
    1. Ishida Y, Aqata Y, Shibahara K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992;11:3887-95. - PMC - PubMed
    1. Dong H, Zhu G, Tamada K, et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999;5:1365-9. 10.1038/70932 - DOI - PubMed
    1. Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001;2:261-8. 10.1038/85330 - DOI - PubMed
    1. Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008;26:677-704. 10.1146/annurev.immunol.26.021607.090331 - DOI - PMC - PubMed

LinkOut - more resources